|
|
||||||||
EDITORIAL FOCUS
1Department of Internal Medicine/Sections of Pulmonary and Critical Care Medicine and 2Molecular Medicine, Departments of 3Microbiology and Immunology and 4Biochemistry, Wake Forest University School of Medicine, Winston-Salem, North Carolina
Submitted 19 July 2004 ; accepted in final form 13 October 2004
Pulmonary surfactant's complex mixture of phospholipids and proteins reduces the work of breathing by lowering alveolar surface tension during respiration. One mechanism of surfactant damage appears to be the hydrolysis of phospholipid by phospholipases activated in the inflamed lung. Humans have several candidate secretory phospholipase A2 (sPLA2) enzymes in lung cells and infiltrating leukocytes that could damage extracellular surfactant. We considered two mechanisms of surfactant disruption by five human sPLA2s, including generation of lysophospholipids and the depletion of specific phospholipids. All five sPLA2s studied ultimately caused surfactant dysfunction. Each enzyme exhibited a different pattern of hydrolysis of surfactant phospholipids. Phosphatidylcholine, the major phospholipid in surfactant and the greatest potential source for generation of lysophospholipids, was susceptible to hydrolysis by group IB, group V, and group X sPLA2s, but not group IIA or IID. Group IIA hydrolyzed both phosphatidylethanolamine and phosphatidylglycerol, whereas group IID was active against only phosphatidylglycerol. Thus, with groups IB and X, the generation of lysophospholipids corresponded with surfactant dysfunction. However, hydrolysis of and depletion of phosphatidylglycerol had a greater correlation with surfactant dysfunction for groups IIA and IID. Surfactant dysfunction caused by group V sPLA2 is less clear and may be the combined result of both mechanisms.
lung injury; asthma; surface tension
This article has been cited by other articles:
![]() |
B. P. Hurley and B. A. McCormick Multiple Roles of Phospholipase A2 during Lung Infection and Inflammation Infect. Immun., June 1, 2008; 76(6): 2259 - 2272. [Full Text] [PDF] |
||||
![]() |
G. Enhorning Surfactant in Airway Disease Chest, April 1, 2008; 133(4): 975 - 980. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Fisher, C. Dodia, S. I. Feinstein, and Y.-S. Ho Altered lung phospholipid metabolism in mice with targeted deletion of lysosomal-type phospholipase A2 J. Lipid Res., June 1, 2005; 46(6): 1248 - 1256. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. G. Cochrane Pulmonary surfactant in allergic inflammation: new insights into the molecular mechanisms of surfactant function Am J Physiol Lung Cell Mol Physiol, April 1, 2005; 288(4): L608 - L609. [Full Text] [PDF] |
||||
![]() |
R. D. Hite, M. C. Seeds, D. L. Bowton, B. L. Grier, A. M. Safta, R. Balkrishnan, B. M. Waite, and D. A. Bass Surfactant phospholipid changes after antigen challenge: a role for phosphatidylglycerol in dysfunction Am J Physiol Lung Cell Mol Physiol, April 1, 2005; 288(4): L610 - L617. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |